Lambda λ轻链（鼠单克隆抗体）

Lambda λ轻链(鼠单克隆抗体) 

广州健仑生物科技有限公司

此抗体和人免疫球蛋白的λ 轻链反应，和κ 轻链无交叉反应。可研究带有λ 轻链的B 淋巴细胞和浆细胞，细胞外的免疫球蛋白λ 轻链也可着色，应注意区分。研究认为B 淋巴细胞肿瘤的共同特征是只限于单个轻链的表达，因此κ 和λ 轻链可用于良恶性淋巴病变(反应性淋巴细胞增生和淋巴瘤)的研究。

我司还提供其它进口或国产试剂盒：登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

欢迎咨询

欢迎咨询

Lambda λ轻链(鼠单克隆抗体) 

【产品介绍】

细胞定位：细胞浆

克隆号：HP6054

同型：IgG

适用组织：石蜡/冰冻

阳性对照：扁桃体

抗原修复：热修复（EDTA）

抗体孵育时间：30-60min

Lambda λ轻链(鼠单克隆抗体) 

想了解更多的产品及服务请扫描下方二维码：

【公司名称】 广州健仑生物科技有限公司
【市场部】     欧

【】 
【腾讯  】 
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室

Wright博士说：“在这一点上，利用端粒酶将有毒产物整合进端粒，是非常鼓舞人心的。”
重要的是，和其他许多端粒酶YZ化合物不同，研究人员并没有在6-thiodGZL小鼠的血液、肝脏和肾脏中观察到严重的副作用。
Shay博士说：“由于端粒酶在几乎所有的人类肿瘤中表达，这项工作提出了一种潜在创新的方法，靶定端粒酶表达的癌细胞，而对正常细胞的毒副作用较小。我们相信这种小分子将填补未知领域中的一个未曾满足的癌症需要，将被迅速应用于临床。”
我们的机体进化出了一些途径来摆脱有缺陷的干细胞。来自科罗拉多大学癌症ZX的研究人员在发表于《干细胞》(Stem Cells)杂志上的一项研究中揭示，其中一条途径就是通过“重编程”使得被辐射损伤的干细胞分化为不再能够长久生存的其他细胞。辐射会使得干细胞丧失它的“干性”。这的确有意义：你不会希望受损的干细胞继续留在这儿生成受损细胞。
这项研究还证实，当全身遭受辐射时清除辐射损伤干细胞的同一“编程”防卫机制导致了血癌生长(延伸阅读：Sci Rep：福岛核辐射后 动物血液出现异常 )。通过重编程这一防卫机制，我们或许能够在全身辐射之后防止癌症。

This antibody and human immunoglobulin lambda light chain reaction, and kappa light chain no cross-reaction. B lymphocytes and plasma cells with a lambda light chain can be studied. Extracellular immunoglobulin lambda light chains can also be colored, and care should be taken to distinguish them. Studies suggest that the common feature of B-lymphoblastic tumors is limited to the expression of a single light chain, so kappa and lambda light chains can be used in the study of benign and malignant lymphopathies (reactive lymphoproliferation and lymphoma).

Dr. Wright said: "At this point, the use of omerase to integrate toxic products into omeres is very encouraging."
Importantly, and many other different omerase inhibiting compound, the researchers did not treat the blood of mice in the 6-thiodG, liver and kidney were observed serious side effects.
Dr. Shay said: "Because omerase is expressed in almost all human tumors, this work presents a potentially innovative approach, targeting cancer cells express omerase, and toxicity to normal cells smaller. We believe that such small molecules will fill an unmet need for cancer in an unknown area and will be rapidly applied to the clinic. "
Our body has evolved ways to get rid of defective stem cells. Researchers from the University Cancer Center in Colorado in a study published in the (Stem Cells) magazine "stem cell" is disclosed, one of which way is by "reprogramming" such that the radiation damage of stem cells into no longer be able to long-term survival Other cells. Radiation can cause stem cells to lose their "dryness." This does make sense: You do not want damaged stem cells to stay there to create damaged cells.
The study also confirmed that the same clear "programming" defense mechanism of radiation damage stem cells resulted in the growth of blood cancer (Further reading: Sci Rep: After the Fukushima nuclear radiation abnormal animal blood) when subjected to whole body radiation. By reprogramming this defense mechanism, we may be able to prevent cancer after systemic radiation.